Skip to main content
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd — Investor Relations & Filings

Ticker · TLSA ISIN · BMG889121031 LEI · 984500769407C5E46F42 US Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2018-10-30 Capital/Financing Update
Country BM Bermuda
Listing US TLSA

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com/

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2018
Capital/Financing Update Classification · 95% confidence The document is a letter from an underwriter representative to the SEC regarding a Registration Statement on Form F-1 for Tiziana Life Sciences plc. It requests acceleration of the effective date of the Registration Statement and provides details about distribution of the Preliminary Prospectus. The content is related to capital raising and securities registration, specifically under the Securities Act of 1933. The document is short (2100 characters) and is a correspondence related to a financing registration, not a full report or prospectus itself. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2018-10-30 English
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for the registration of certain classes of securities pursuant to Section 12(b) of the Securities Exchange Act of 1934. It describes the registration of American Depositary Shares and ordinary shares on NASDAQ. The document is a registration statement, not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and does not fit into categories like Annual Report, Earnings Release, or Capital Update. Therefore, it best fits the Regulatory Filings (RNS) category as a general SEC filing that does not fall into other specific categories.
2018-10-30 English
AMENDMENT NO. 5 TO REGISTRATION STATEMENT
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 5 to a Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). The Form F-1 is a registration statement used by foreign private issuers to register securities for an initial public offering (IPO) under the Securities Act of 1933. The text includes detailed information about the offering, the company, underwriting, risk factors, and financial data, typical of a registration statement prospectus. This is not an annual report, earnings release, or any other type of financial report but a regulatory filing related to securities registration for an IPO. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes registration statements and amendments thereto.
2018-10-29 English
Regulatory Filings 2018
Regulatory Filings Classification · 100% confidence The document is a Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 filed with the U.S. Securities and Exchange Commission. It relates to the registration of American Depositary Shares evidenced by American Depositary Receipts (ADRs) for Tiziana Life Sciences plc. The Form F-6 is a registration statement used to register ADRs under the Securities Act of 1933. The document includes details about the deposit agreement, terms of deposit, fees, and signatures of authorized representatives. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under Regulatory Filings (RNS).
2018-10-29 English
Regulatory Filings 2018
Regulatory Filings
2018-10-23 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from the company and its legal counsel responding to comments from the U.S. Securities and Exchange Commission staff regarding a Registration Statement on Form F-1, specifically Amendment No. 3 and Amendment No. 4. The content focuses on addressing SEC comments about disclosures and financial presentation in the registration statement. There is no actual financial data or report content presented here; rather, it is a correspondence letter responding to regulatory review comments. This type of document is a regulatory filing related to the registration statement process, not the registration statement itself or a financial report. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (5610 characters) and content confirm it is not a brief announcement or a full report but a detailed response letter to the SEC.
2018-10-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.